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ABSTRACT
Warfarin remains the oral anticoagulant of choice in sub-Saharan Africa. However, dosing is 
challenging due to a highly variable clinical response for a given dose. This study aimed to 
develop and validate a clinical warfarin dose-initiation model in sub-Saharan Black-African 
patients. For the development cohort, we used data from 364 patients who were recruited from 
8 outpatient clinics and hospital departments in Uganda and South Africa (June 2018–July 2019). 
Validation was undertaken using the International Warfarin Pharmacogenetics Consortium 
(IWPC) dataset (690 Black patients). Four predictors (age, weight, target International 
Normalized Ratio range and HIV status) were included in the final model which achieved mean 
absolute errors (MAEs, mean of absolute differences between true  dose and dose predicted by 
the model) of 11.6 (95% CI 10.4 to 12.8) and 12.5 (11.6 to 13.4) mg/week in the development 
and validation cohorts respectively. Two other clinical models, IWPC and Gage, respectively 
obtained MAEs of 12.5 (11.3 to 13.7) and 12.7 (11.5 to 13.8) mg/week in the development 
cohort, and 12.1 (11.2 to 13.0) and 12.2 (11.4 to 13.1) mg/week in the validation cohort. 
Compared to fixed dose-initiation, our model decreased the percentage of patients at high risk of 
suboptimal anticoagulation by 7.5% (1.5% to 13.7%) and 11.9% (7.1% to 16.8%) in the 
development and validation cohorts, respectively. The clinical utility of this model will be tested 




Warfarin remains the most widely used oral anticoagulant worldwide, even after the  
introduction of new oral anticoagulants.1 In sub-Saharan Africa and other low-income countries, 
it remains preferred due to its significantly lower cost.2 However, warfarin dosing is challenging 
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response for a given dose. Moreover, poor anticoagulation can lead to thrombotic or bleeding 
events if the International Normalized Ratio (INR), a measure of blood coagulation ability, is 
below or above therapeutic range, respectively. It is therefore unsurprising that warfarin is an 
important cause of preventable adverse drug reaction (ADR)-related hospitalizations in South 
Africa. For example, in a study by Mouton et al, 164 (8%) of 1951 hospitalizations were ADR-
related, and of these, 11 were due to warfarin, which was the most commonly implicated drug.3 
To improve the accuracy of warfarin dosing, several dose-prediction models that include clinical, 
demographic and environmental factors such as age, height, weight and interacting drugs as well 
as genetic factors such as polymorphisms in the genes CYP2C9 (cytochrome P450, family 2, 
subfamily C, polypeptide 9), and VKORC1 (vitamin K epoxide reductase complex, subunit1) have 
been developed.4 Clinical dosing models include only clinical, demographic and environmental 
factors whereas pharmacogenetic models additionally incorporate genetic factors. To date, most 
models have been developed in Whites and these may not be applicable to sub-Saharan African 
populations. 
The need for dose-prediction models that are applicable to sub-Saharan African patients is 
emphasized by the poor quality of warfarin anticoagulation (defined as having a time in 
therapeutic INR range [TTR] of less than 65%5) in this region. In an earlier study in South Africa 
and Uganda, we observed that the median TTR was 41% (range 35% to 48%),6 similar to previous 
reports in this region.7-10 This is quite low when compared to our previous experience with an 
European cohort (mean TTRs of 60% [fixed-dose initiation] and 67% [genotype-guided dosing]).11 
To improve warfarin anticoagulation through optimizing dosing, we therefore aimed to develop 
and validate a clinical warfarin dose-initiation model for sub-Saharan African patients.
METHODS
This reporting follows the TRIPOD (Transparent Reporting of a multivariable prediction model for 
Individual Prognosis Or Diagnosis) statement12 (checklist in Table S1). Although the TRIPOD 
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recommendations and reporting items equally apply to the development and validation of dose 
prediction models.12 
Source of data
The dataset used for developing the dose-initiation model, the so-called ‘development cohort’ 
comprised 364 warfarin-treated patients. They were recruited between June 2018 and July 2019 
as part of an observational study being conducted in Uganda and South Africa (ClinicalTrials.gov 
Identifier: NCT03512080) by the National Institute of Health Research (NIHR) Global Health 
Research Group on WARfarin anticoagulation in PATients in Sub-SaHaran Africa (War-PATH; 
http://warpath.info/).  This is a collaboration between the University of Liverpool, Infectious 
Diseases Institute (Makerere University, Uganda) and the University of Cape Town (South Africa). 
The study complies with the Declaration of Helsinki13 and was approved by Institutional Review 
Boards (IRB) of the University of Liverpool (UK; ref:  2934), University of Cape Town (South Africa; 
ref:  672/2017), and Joint Clinical Research Centre (Uganda; ref: JC3017). Additionally, work in 
Uganda was approved by the Uganda National Council for Science and Technology (ref: 
HS164ES).  IRB approval and written individual-patient informed consent were obtained before 
patient enrolment. 
The dataset used for validating the dose-initiation model, the so-called ‘external validation 
cohort’, comprised data from the International Warfarin Pharmacogenetics Consortium (IWPC) 
study which collated individual patient data from participants in 9 countries (four continents).14 
The IWPC ethnicity dataset containing detailed de-identified curated demographic, clinical and 
genetic data from 6922 multiethnic chronic warfarin users was downloaded from the 
PharmacoGenomics KnowledgeBase (PharmGKB) website 
(https://www.pharmgkb.org/downloads, under the sub-heading “International Warfarin 
Pharmacogenetics Consortium (IWPC)”).      
Participants
The War-PATH study population consisted of warfarin-treated patients of self-reported Black-
African ethnicity who were recruited from 8 outpatient clinics and hospital departments (Table 
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venous thromboembolism (VTE) or atrial fibrillation (AF) with a target International Normalised 
Ratio (INR) range 2.0–3.0; or (b) valvular heart disease with a target INR range 2.5–3.5. Patients 
were only included if they had attained the outcome of interest (the stable warfarin dose, as 
defined below). As the purpose of the model was to predict what a patient’s stable dose was 
going to be, patients having never achieved stable warfarin dose as defined below were 
excluded. Patients who were unwilling to take part, pregnant women or patients with any other 
contraindications based on clinician judgement were also excluded.
The study design and eligibility criteria for the IWPC study have previously been reported.14 For 
the external validation cohort, we only included patients who were Black or African American 
and had a target INR of either 2.5 or 3.0 (where not available, target INR was estimated based on 
treatment indication).  
Outcome
The outcome of interest was stable warfarin dose, defined for the development cohort as the 
same dose for two consecutive clinic visits in the 12 months preceding recruitment, with the INR 
being in therapeutic range at each of those visits. War-PATH study case report forms were used 
to capture weekly stable dose as well as other variables described below. The IWPC study sites 
used different definitions for warfarin stable dose, most requiring a dose that produced stable 
anticoagulation levels (measured using INR) over a defined time period.14 
Predictors
As part of the observational study (details above), the following data were captured for each 
War-PATH patient during enrolment: country of recruitment, age, weight, height, gender, 
employment status, annual individual/household income, education status, housing type, 
distance between residence and health centre, time taken to travel from home to health centre, 
indication for anticoagulation (used to infer the target INR range), smoking status, alcohol intake 
per week, renal biomarker data (serum creatinine and estimated glomerular filtration rate), liver 
biomarker data (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl 
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concomitant medications including herbal/complementary, traditional or “over-the counter” 
medications. 
Sample size
During model development, all available data (n = 364) was used to maximise the power and 
generalisability of the results. To avoid the risks of over- and under-fitting, the study participant-
per-candidate predictor parameter was set at 20.15 Consequently, we could only consider a 
maximum of 18 candidate predictor parameters. For model validation, again all eligible patients 
were included.
Missing data
Missing data was defined as the absence of data values within a specific variable category in the 
case report form.  Variables coded as ‘unknown’ (e.g. for HIV status) were therefore not 
considered as missing. Again, to maximize power and generalizability of the results, we did not 
exclude cases with missing data for any of the included predictor variables. Rather we assumed 
that missing data occurred at random and performed Multivariate Imputation by Chained 
Equations (MICE) within R.16 The included predictor variables and outcome variable17 were used 
to impute missing data using predictive mean matching for continuous variables and logistic 
regression for binary/categorical variables. Following the recommendation to have the imputed 
datasets to at least equal the percentage of incomplete cases,18 we created multiple datasets 
which were identical except for the imputed values to reflect the uncertainty associated with 
each of the imputations. The estimates derived from these datasets were combined using 
Rubin’s rules.19  
Statistical analysis methods
Multivariable linear regression models were fitted using four regression approaches (ordinary 
least squares, quantile regression, weighted quantile regression and non-linear least squares) on 
the development cohort. Starting with a list of potential variables, all possible linear models were 
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the mean of the absolute values for the difference between predicted and stable doses), mean 
absolute percentage error (MAPE) and logarithmic ratio of estimate to actual value. Bootstrap 
validation was applied to correct overfitting and the final models were externally validated in the 
IWPC cohort. In both development and external validation cohorts, we compared our models 
with current warfarin initiation practice in sub-Saharan Africa (fixed dose of 35 mg/week) and 
two widely known dose prediction models (the IWPC14 and Gage20 models). Other performance 
indices were also employed for this purpose, including the percentage of patients with ideal dose 
(defined as predicted dose within 20% of actual dose) and the coefficient of determination (R2) to 
respectively enable us to assess the clinical relevance and fit accuracy of the model. Bias was 
assessed using a measure derived from the mean of the logarithm of the accuracy ratio while 
clinical safety was computed as the percentage of patients at risk of under- or over-dosing 
(defined as having an actual dose at least 40% lower or higher than the predicted dose 
respectively – see Text S3 for justification in choosing 40%). Where we computed the difference 
between the mean performance of our model and that of a comparator model, statistical 
significance was considered as 95% confidence intervals that did not contain zero. Texts S1-S3 
provide a detailed explanation of the analysis methods and metrics employed. All analyses were 
conducted in R version 3.6.121 (R code used is available in Text S4).
Sensitivity analysis 
Because our model and the Gage model required age as a continuous variable and yet the IWPC 
dataset had categorized it (age recorded in decades), we made an assumption that the age 
corresponded to the lower-class boundary (e.g. for the decade of 20 to 29 years, the age was 
considered to be 20). To test the accuracy of this assumption, we conducted sensitivity analyses 
in which the age was taken as the midpoint value (e.g. 24.5 years) or upper-class boundary (e.g. 
29 years). For the first decade (10 to 19 years), the lower-class boundary and midpoint values 
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We included the 364 patients that had been recruited by 31st July 2019, and characteristics of all 
patients are presented in Table 1. The flow diagram for the IWPC patients included in the 
external validation cohort is shown in Figure S1.
Model development and specification
Figure 1 summarizes the predictor selection process. Based on expert guidance and literature 
review, we considered three predictors (age, weight, and target INR range) to have higher clinical 
relevance and therefore these were not subjected to selection during the modeling stage.  Four 
other predictors including country of recruitment, gender, HIV status and 
simvastatin/amiodarone status were also selected for use during the modeling process. HIV-
status had three factor levels, and this translated into a study participant-per-candidate predictor 
parameter of 45.6. Amongst these seven predictor variables, only 3.0% (n = 11) cases were 
missing data with all cases missing weight (Figure S2–S3). 
The performances of the best 3-, 4-, 5-, 6- and 7-variable models for each of the four regression 
approaches are shown in Figure S4. For ordinary least squares, quantile regression and non-linear 
least squares, the 4-variable models (predictors: age, weight, target INR, and HIV status) were 
preferable in terms of the mean absolute error (MAE) or the mean absolute logarithm of the 
accuracy ratio (MALAR) and model parsimony. For weighted quantile regression, the 3-variable 
models (predictors: age, weight, and target INR) were chosen based on the mean absolute 
percentage error (MAPE). Since each regression approach fitted non-transformed, square-root 
and logarithmic doses, 12 models in total were selected. The performances of these models in 
terms of the MAE, MAPE and the logarithm of the accuracy ratio-derived measures are shown in 
Table S3. We chose the 4-variable model (original coefficients in Table S4) fitted using non-linear 
least squares and non-transformed dose (details in Table S3).  Applying a shrinkage factor of 
0.8892 to the coefficients of this model produced a shrunken model (Weekly dose in mg = 
20.2832 – 0.0656 x Age [years] + 0.2178 x Weight [kg] + 7.3190 [if Target INR range is 2.5 to 3.5] 
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The performances of the War-PATH, IWPC, Gage and fixed-dose (35 mg/wk) models in the 
development and validation cohorts are shown in Table 3 (the performance of the War-PATH 
model using its original coefficients is shown in Table S5). The War-PATH model, compared to 
fixed dose-initiation, provided dose estimates that were closer to the actual doses (as shown by a 
lower MAE) in both the development (11.6 [95% CI 10.4; 12.8] vs 12.3 [10.9; 13.7] mg/week) and 
external validation (12.5 [11.6; 13.4] vs 13.8 [12.7; 14.9] mg/week) cohorts. However, these 
reductions (respectively 0.7 [-1.1; 2.5] and 1.3 [-0.1; 2.8] mg/wk) were not statistically significant. 
A similar trend was observed with the ‘unbiased’ MAPE: War-PATH vs fixed dose-initiation 
predicted doses were on average within 34.0% (31.0%; 37.2%) vs 36.5% (32.7%; 40.5%) of the 
actual doses in the development cohort and within 35.5% (33.0%; 38.1%) vs 40.1% (37.1%; 
43.1%) of the actual doses in the validation cohort. Only the difference in the validation cohort (a 
MAPE reduction of 4.6% [0.7%; 8.5%]) was statistically significant. In terms of biasness of 
predictions, the War-PATH model (bias of 0.3% [-3.5%; 4.2%] above the actual dose) was 
unbiased (95% CIs contained zero) while fixed dose-initiation systematically underpredicted 
(5.8% [1.8%; 9.6%] below the actual dose) in the development cohort. In the validation cohort, 
our model systematically overpredicted (4.3% [1.4%; 7.3%] above the actual dose) while fixed 
dose-initiation underpredicted (9.5% [6.6%; 12.3%] below the actual dose). The bias of our model 
in the validation cohort was, however, eliminated when the age was taken as the upper-class 
boundary (predicted doses 2.8% [-0.1%; 5.7%] above the actual) (Table S6). 
Regarding the MAE and unbiased MAPE, our model performed slightly better than the IWPC and 
Gage models in the development cohort and similarly in the external validation cohort as 
summarized in Table 3. The IWPC and Gage models systematically over-predicted in the 
development cohort (predicted doses were, respectively, on average 7.5% [3.2%; 12.0%] and 
13.3% [8.9%; 17.9%] above the actual doses). In the IWPC validation cohort; however, only the 
Gage model retained this bias (predicted doses 9.7% [6.7%; 12.9%] above the actual) and this 
bias was eliminated when age was taken as the upper-class boundary (predicted doses 2.6% [-
0.2%; 5.5%] above the actual) (Table S6). Our model’s fit accuracy (R2) was comparable to these 
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[7.2; 18.5] vs 15.6 [9.0; 22.3]) but the worst in the validation cohort (War-PATH vs IWPC vs Gage: 
12.2 [9.9; 14.5] vs 23.5 [19.1; 27.9] vs 24.2 [18.9; 29.5]).  
Clinical relevance and safety
Our model (41.3% [95% CI 36.2%; 46.3%] performed slightly better than the IWPC (37.5% [32.4%; 
42.6%]) and Gage (37.3% [32.4%; 42.4%]) models in terms of the percentage of patients with 
ideal dose in the development cohort (performance was similar in the validation cohort, Table 3). 
Consequently, it was the preferred clinical model to consider for implementation in South Africa 
and Uganda.
Compared to existing clinical practice (fixed dose-initiation with 35 mg/wk), our model 
performed slightly worse in the development cohort (2.7% [-4.4%; 9.8%] less patients with ideal 
dose) but slightly better in the validation cohort (2.0% [-3.3%; 7.3%] more patients with ideal 
dose). The differences in the performance of the War-PATH model and fixed dose-initiation in 
the low (≤21 mg/wk), intermediate (>21 and <49 mg/wk), and high (≥49 mg/wk) dose groups are 
shown in Figure 2 (percentage of patients with ideal dose) and Table S7 (percentage of patients 
with ideal, underestimated or overestimated doses). Neither of these approaches were able to 
predict ideal dose in the low dose groups, in either of the cohorts. In the development cohort, 
our model was better than fixed dose-initiation in the high dose group (19.7% [11.5%; 27.9%] 
more patients with ideal dose) but this came at the expense of the performance in the 
intermediate dose group (12.3% [3.6%; 20.7%] less patients with ideal dose). A similar trend was 
observed in the validation cohort (respective differences of 29.5% [23.3%; 35.8%] and 10.7% 
[4.2%; 17.3%]).
With the IWPC dose thresholds, 32 and 97 patients in the development cohort respectively 
required ≤21 mg/wk and ≥49 mg/wk (Figure 2). This translates into 8.8% and 26.6% of the 
patients in the development cohort being at high risks of over- and under-anticoagulation 
respectively (or a total of 35.4% of the patients being at risk of sub-optimal anticoagulation). On 
the other hand, only 27.9% of the development cohort was computed as being at risk of sub-
optimal anticoagulation with our model.  This implies that using our model would reduce the 
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the same as the increase in the number of patients in the ‘low risk’ dose group, Figure 3). In the 
validation cohort, fixed dosing would place 37.6% of the patients at a risk of sub-optimal 
anticoagulation and as for the development cohort, our model would decrease this figure by 
11.9% (7.1%; 16.8%).
DISCUSSION
Warfarin dosing remains challenging due to a narrow therapeutic window and large intra- and 
interpatient variability in dose requirements due to clinical and genetic factors. Initial dosing (e.g. 
5 mg/day) is often empirical with dose adjustments made until the patient is within therapeutic 
range. However, during this time, patients are at an increased risk of bleeding or 
thromboembolic events if too much or too little warfarin is prescribed, respectively.4 To facilitate 
warfarin dose-initiation in two of the underrepresented sub-Saharan African populations, we 
have developed a dose-initiation model that includes four clinical factors namely age, weight, 
target INR range and HIV status. Three of these (age, weight and target INR) have established 
relationships with warfarin dose and have been included in many other models1,22-24 and so were 
not subjected to selection during the modeling process. Of the variables subjected to selection, 
HIV status was the most important predictor as evidenced by its inclusion in the final model. Of 
note, HIV status was represented in the model as a categorical variable with three levels – 
negative, positive and HIV status unknown. Including the third category allows for the possibility 
of using the model even where a patient refuses an HIV test. Given the HIV infection prevalence, 
albeit highly variable,25 in African countries (10% in Ugandans and 22% in South Africans in this 
study), it was important to include this in our model.  HIV infection per se can lead to a 
hypercoagulable state26-30 resulting in increased dose requirements. However, doses may also 
change because of interactions with antiretroviral drugs. 
Compared to current practice in these two countries (fixed dose-initiation), this clinical model 
decreased the percentage of patients at high risk of suboptimal anticoagulation by 7.5% and 
11.9% in the development and validation cohorts, respectively. The greatest benefits were seen 
in the patients at high risk of under-anticoagulation – patients who are predisposed to 
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risk of over-anticoagulation, this clinical model performed similarly to fixed dose-initiation which 
implies it needs further development to improve prediction. 
Genetic variants in the CYP2C9 and VKORC1 genes account for about 40% of the variance in daily 
warfarin dose requirement.31 In a systematic review, we have recently quantified the effect of 
genetic variants in the CYP2C9 and VKORC1 genes that are more prevalent in Black-African 
populations,32 and it would be expected that inclusion of these variants to the model should 
improve prediction for all patients. In order to test this, we will be developing a pharmacogenetic 
model during the ongoing collaborative project in Uganda and South Africa (WARfarin 
anticoagulation in PATients in Sub-SaHaran Africa; http://warpath.info/). 
Based on the mean absolute error (MAE), unbiased mean absolute percentage error, and 
percentage of patients with ideal dose, our model performed better than two of the most 
popular clinical models (the Gage and IWPC models) in the development cohort and comparably 
in the external validation cohort. Although the IWPC model was developed in a subgroup of 
patients with a target INR range of 2.0–3.0, we also tested it in patients with a target INR range 
of 2.5–3.5 since testing a prediction model in a completely different clinical setting (domain 
validation) is an accepted form of external validation.33 We did not compare the performance of 
our model with any of the existing pharmacogenetic models but based on previous studies, 
current pharmacogenetic models may not work better than this clinical model in this patient 
group. For example, a race-based evaluation of the IWPC dataset using the IWPC, Gage and 
eleven other pharmacogenetic models revealed that the MAE was 12.0–21.0 mg/wk in Blacks34 
(estimates of MAE in this study were 12.5 mg/wk in the external validation cohort). Liu et al.35 
made similar observations when they reanalyzed the IWPC dataset using nine different machine 
learning techniques (MAEs for the pharmacogenetic models were 12.2–13.8 mg/wk for Blacks). 
In terms of the coefficient of determination (R2), our model (15%) performed similarly to the 
IWPC (13%) and Gage (17%) models in the development cohort, but worse in the validation 
cohort (12% vs 24% and 24%, respectively). Importantly, the R2 which relates to the proportion of 
the variance explained by a model was not our primary metric. This is because the value of a 
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fixed dose-initiation with an R2 that is close to zero is considered useful when the MAE is 
considered.
There are limitations to our study.  We excluded unstable patients from our study which may 
limit the generalizability of the model. However, patients with unstable dose do not have an 
outcome variable value and therefore could not be included in the prediction model we 
developed. Second, our dose-initiation model cannot be used during the dose-revision period. 
For this, national treatment guidelines39 or published guidelines40,41 are available. Third, we 
excluded other relevant well-known variables such as body mass index, adherence and vitamin K 
status that have previously been found to be important in influencing stable dose mostly because 
they were unavailable, expensive to capture or missing in a large proportion of patients – which 
would have affected implementation. Fourth, we did not study children, where to date, no 
dosing model with clinical utility has been developed in any ethnic group. Lastly, our analysis did 
not address whether precise initial dosing would result in reduction in the time to attain and/or 
time in stable therapeutic INR. 
We will be implementing this model in a prospective cohort of Ugandan and South African 
patients where a clinical decision has been made to start warfarin. We anticipate that 
implementing a consistent dose-initiation model will improve time in therapeutic range (TTR) and 
other clinical outcomes as demonstrated by studies in Western nations.42 It is important to note 
that even modest TTR improvements can have significant benefits on clinical outcomes and cost 
as demonstrated by Rose et al.43 who showed that in a population of 67,077 atrial fibrillation 
patients, a 5% improvement will prevent nearly 200 ischemic strokes, over 600 deaths and close 
to $16 million per year. 
To our knowledge, we have developed the first warfarin dose-initiation clinical model for sub-
Saharan African patients. It performs better than fixed dosing in terms of more accurate dosing 
and puts less patients at risk of suboptimal anticoagulation. We hope that its implementation 
and validation in a prospective cohort will inform future large-scale implementation. Our long-
term aim is to also evaluate the importance of genetic variants in improving warfarin dosing and 
anticoagulation in patients in Uganda and South Africa.  Given that genetic testing is not readily 
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clinical dosing model is more important in the near-term.  However, it is also important to ensure 
that genomic medicine does not bypass developing countries as this will exacerbate health 
inequalities.  
STUDY HIGHLIGHTS 
What is the current knowledge on the topic?
Warfarin dosing remains challenging due to a highly variable clinical response for a given dose.
What question did this study address?
Can a clinical dose-initiation model be developed and validated for sub-Saharan Black-African 
patients?
What does this study add to our knowledge?
We have developed the first warfarin dose-initiation clinical model for Black-African patients in 
Uganda and South Africa.
How might this change clinical pharmacology or translational science?
We will be implementing and validating this model in a prospective cohort to inform future large-
scale implementation. More optimized dosing should improve the quality of warfarin 
anticoagulation in these two developing countries.
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FIGURE LEGENDS
Figure 1. Selection of predictors. aThe exception was simvastatin (a known warfarin potentiating 
drug) being taken by 9.3% of the patients which was combined with amiodarone (another 
warfarin potentiating drug) to meet this 10% requirement.
Figure 2. Percentage of patients with ideal dose. Error bars represent 95% confidence intervals. 
The ideal dose was defined as the predicted dose within 20% of the actual dose while the fixed 
dose was 35 mg of warfarin per week.
Figure 3. Percentage of patients put at risk of either under- or over-anticoagulation by the 
different dosing strategies.
SUPPLEMENTARY FILES
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Table 1. Patient characteristics. 
Variables Development cohort 
(n = 364) 
External validation cohort 
(n = 690) 








Age (years) Mean (SD) 
Median (IQR) 
Range  
46.2 (15.3)   
























































































































































Those with heart valve disorders have a higher target range (2.5–3.5) than the rest (2.0–3.0) who include those with atrial 
fibrillation and venous thromboembolism. 
b
Includes those taking carbamazepine, phenytoin, rifampicin, or rifampin. IQR = 
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 20.2832 0.7918 Intercept 
- 0.0656 0.0761 Age 
+ 0.2178 0.0708 Weight 
+ 7.3190 1.6369 Target INR range 
+ 8.7973 2.5944 HIV Positive 
+ 3.4054 3.4353 HIV Unknown 
= Weekly warfarin dose
d 
a
A shrinkage factor of 0.8892 (SD 0.0578) was applied to the coefficients of Age, Weight, Target INR range, HIV Positive and HIV 
Unknown, and the intercept re-estimated. 
 b
SDs were computed using bootstrapping (at least 1000 replicates). Except for the 
intercept (re-estimation SD used), SDs incorporate the SD of the shrinkage factor.
 c
For Age, input age in years; Weight, input 
weight in kg; Target INR range, input 0 if target INR is 2.0–3.0 and 1 if target INR is 2.5–3.5; HIV Positive, input 0 if HIV negative 
or HIV unknown and 1 if HIV positive; and for HIV Unknown, input 0 if HIV negative and HIV positive and 1 if HIV unknown. 
d
Predicted doses are rounded off to the nearest 2.5 mg/week. HIV = human immunodeficiency virus; INR = international 
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Table 3. Performance of the clinical models and fixed dose-initiationa 
Model Development cohort (N = 364)
b 
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0.0 (0.0; 0.0) 
a
When referring to development and validation cohorts, this is in relation to the War-PATH model e.g. since part of the external validation cohort is IWPC’s and Gage’s development cohorts. 
 
b




Unbiased MAPE = (exp(mean(absolute(log(predicted dose/actual dose)))) – 1) × 100. 
d
Bias = (exp(mean(log(predicted 
dose/actual dose))) – 1) × 100 (negative and positive values imply under- and over-estimation respectively). 
e
The ideal dose was defined as the predicted dose within 20% of the actual dose. 
f
The fixed dose was 35mg of warfarin per week. CI = confidence intervals; IWPC = International Warfarin Pharmacogenetics Consortium; MAE = mean absolute error; MAPE = mean absolute 
percentage error; R
2











 Predictors collected in War-PATH 
observational study (N > 26) 
Predictors used during modeling (n = 7) 
• No predictor selection for age (in years), weight (in 
kg) and target INR (coded 1 if 2.5–3.5, else 0) during 
modeling (included in all models based on clinical 
importance and expert opinion) 
• Predictor selection for country of recruitment (1 if 
Uganda), gender (1 if male), HIV status (dummy 
coded 1 if positive/unknown) and 
simvastatin/amiodarone status (1 if taking)  
 
Reasons for exclusions 
Extensive missing data (not available in >10% of the patients): 
predictor (% of patients with missing data) 
• height (45%) 
• annual household income (85%) 
• distance between residence and health centre (49%) 
• urea (92%) 
• estimated glomerular filtrate rate (49%) 
• alanine aminotransferase (12%) 
• aspartate aminotransferase (96%) 
• gamma-glutamyl transferase (97%) 
• total bilirubin (96%) 
• albumin (97%) 
Expert guidance and literature review 
• employment status 
• education status 
• housing type 
• time taken to travel from home to health centre 
• co-morbidities or any co-medications 
Power 
• co-morbidities or any co-medications (present in or taken by 
<10% patients)a e.g. tuberculosis positive in only 2 (<1%) 
patients 
• alcohol consumption (only 23 (9%) people drank more than 1 
alcohol unit per week) 
• smoking (only 17 (5%) current smokers) 
Other 
• serum creatinine (reliability/uncertainty of time of 
measurement, and measurement costs/burdens) 
Predictors in final multivariable 
prediction model (n = 4) 
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